An overview of the c-MET signaling pathway

Therapeutic Advances in Medical Oncology

Volumn 3, Issue 1, 2011, Pages S7-S19

  Organ, Shawna Leslie ^a   Tsao, Ming Sound ^a  

^a NONE

Author keywords

c MET; cancer; hepatocyte growth factor (HGF); MET; receptor tyrosine kinase; signaling

Indexed keywords

EID: 84997941720     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834011422556     Document Type: Review

References (118)

1. Abounader R. Reznik T. Colantuoni C. Martinez-Murillo F. Rosen E.M. Laterra J. (2004) Regulation of c-Met-dependent gene expression by PTEN. Oncogene 23: 9173–9182.
2. Bachleitner-Hofmann T. Sun M.Y. Chen C.T. Tang L. Song L. Zeng Z. (2008) HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 7: 3499–3508.
3. Basilico C. Arnesano A. Galluzzo M. Comoglio P.M. Michieli P. (2008) A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem 283: 21267–21277.
4. Bean J. Brennan C. Shih J.Y. Riely G. Viale A. Wang L. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104: 20932–20937.
5. Benvenuti S. Lazzari L. Arnesano A. Li Chiavi G. Gentile A. Comoglio P.M. (2011) Ron kinase transphosphorylation sustains MET oncogene addiction. Cancer Res 71: 1945–1955.
6. Bertotti A. Bracco C. Girolami F. Torti D. Gastaldi S. Galimi F. (2010) Inhibition of Src impairs the growth of met-addicted gastric tumors. Clin Cancer Res 16: 3933–3943.
7. Bertotti A. Comoglio P.M. Trusolino L. (2005) Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. Cancer Res 65: 10674–10679.
8. Bhowmick N.A. Neilson E.G. Moses H.L. (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432: 332–337.
9. Birchmeier C. Birchmeier W. Gherardi E. Vande Woude G.F. (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915–925.
10. Bladt F. Riethmacher D. Isenmann S. Aguzzi A. Birchmeier C. (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376: 768–771.
11. Boccaccio C. Ando M. Tamagnone L. Bardelli A. Michieli P. Battistini C. (1998) Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391: 285–288.
12. Boccaccio C. Gaudino G. Gambarotta G. Galimi F. Comoglio P.M. (1994) Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. J Biol Chem 269: 12846–12851.
13. Boon E.M. van der Neut R. van de Wetering M. Clevers H. Pals S.T. (2002) Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 62: 5126–5128.
14. Comoglio P.M. Giordano S. Trusolino L. (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7: 504–516.
15. Comoglio P.M. Trusolino L. (2002) Invasive growth: from development to metastasis. J Clin Invest 109: 857–862.
16. Conrotto P. Corso S. Gamberini S. Comoglio P.M. Giordano S. (2004) Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 23: 5131–5137.
17. Cooper C.S. Park M. Blair D.G. Tainsky M.A. Huebner K. Croce C.M. (1984) Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311: 29–33.
18. Corso S. Comoglio P.M. Giordano S. (2005) Cancer therapy: can the challenge be MET?. Trends Mol Med 11: 284–292.
19. Danilkovitch-Miagkova A. Zbar B. (2002) Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 109: 863–867.
20. Di Renzo M.F. Olivero M. Ferro S. Prat M. Bongarzone I. Pilotti S. (1992) Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 7: 2549–2553.
21. Di Renzo M.F. Olivero M. Giacomini A. Porte H. Chastre E. Mirossay L. (1995a) Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clinical Cancer Res 1: 147–154.
22. Di Renzo M.F. Olivero M. Katsaros D. Crepaldi T. Gaglia P. Zola P. (1994) Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer 58: 658–662.
23. Di Renzo M.F. Olivero M. Serini G. Orlandi F. Pilotti S. Belfiore A. (1995b) Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. J Endocrinol Invest 18: 134–139.
24. Di Renzo M.F. Poulsom R. Olivero M. Comoglio P.M. Lemoine N.R. (1995c) Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 55: 1129–1138.
25. Engelman J.A. Zejnullahu K. Mitsudomi T. Song Y. Hyland C. Park J.O. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039–1043.
26. Epstein J.A. Shapiro D.N. Cheng J. Lam P.Y. Maas R.L. (1996) Pax3 modulates expression of the c-Met receptor during limb muscle development. Proc Natl Acad Sci USA 93: 4213–4218.
27. Fischer O.M. Giordano S. Comoglio P.M. Ullrich A. (2004) Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem 279: 28970–28978.
28. Fixman E.D. Fournier T.M. Kamikura D.M. Naujokas M.A. Park M. (1996) Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein. J Biol Chem 271: 13116–13122.
29. Follenzi A. Bakovic S. Gual P. Stella M.C. Longati P. Comoglio P.M. (2000) Cross-talk between the proto-oncogenes Met and Ron. Oncogene 19: 3041–3049.
30. Forbes S.A. Bhamra G. Bamford S. Dawson E. Kok C. Clements J. (2008) The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet Chapter 10, Unit 10.11.
31. Furukawa T. Duguid W.P. Kobari M. Matsuno S. Tsao M.S. (1995) Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am J Pathol 147: 889–895.
32. Gambarotta G. Boccaccio C. Giordano S. Ando M. Stella M.C. Comoglio P.M. (1996) Ets up-regulates MET transcription. Oncogene 13: 1911–1917.
33. Gandino L. Di Renzo M.F. Giordano S. Bussolino F. Comoglio P.M. (1990) Protein kinase-c activation inhibits tyrosine phosphorylation of the c-met protein. Oncogene 5: 721–725.
34. Gandino L. Longati P. Medico E. Prat M. Comoglio P.M. (1994) Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. J Biol Chem 269: 1815–1820.
35. Gandino L. Munaron L. Naldini L. Ferracini R. Magni M. Comoglio P.M. (1991) Intracellular calcium regulates the tyrosine kinase receptor encoded by the MET oncogene. J Biol Chem 266: 16098–16104.
36. Garcia-Guzman M. Dolfi F. Zeh K. Vuori K. (1999) Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1 - Crk signaling complex formation. Oncogene 18: 7775–7786.
37. Graziani A. Gramaglia D. dalla Zonca P. Comoglio P.M. (1993) Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. J Biol Chem 268 9165–9168.
38. Guo A. Villen J. Kornhauser J. Lee K.A. Stokes M.P. Rikova K. (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 105: 692–697.
39. Hammond D.E. Hyde R. Kratchmarova I. Beynon R.J. Blagoev B. Clague M.J. (2010) Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks. J Proteome Res 9: 2734–2742.
40. Hara T. Ooi A. Kobayashi M. Mai M. Yanagihara K. Nakanishi I. (1998) Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 78: 1143–1153.
41. Hiscox S.E. Hallett M.B. Puntis M.C. Nakamura T. Jiang W.G. (1997) Expression of the HGF/SF receptor, c-met, and its ligand in human colorectal cancers. Cancer Invest 15: 513–521.
42. Houldsworth J. Cordon-Cardo C. Ladanyi M. Kelsen D.P. Chaganti R.S. (1990) Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 50: 6417–6422.
43. Hu B. Guo P. Bar-Joseph I. Imanishi Y. Jarzynka M.J. Bogler O. (2007) Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 26: 5577–5586.
44. Hui A.Y. Meens J.A. Schick C. Organ S.L. Qiao H. Tremblay E.A. (2009) Src and FAK mediate cell-matrix adhesion-dependent activation of Met during transformation of breast epithelial cells. J Cell Biochem 107: 1168–1181.
45. Ivan M. Bond J.A. Prat M. Comoglio P.M. Wynford-Thomas D. (1997) Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 14: 2417–2423.
46. Jo M. Stolz D.B. Esplen J.E. Dorko K. Michalopoulos G.K. Strom S.C. (2000) Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275: 8806–8811.
47. Khoury H. Naujokas M.A. Zuo D. Sangwan V. Frigault M.M. Petkiewicz S. (2005) HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell 16: 550–561.
48. Kitajima Y. Ide T. Ohtsuka T. Miyazaki K. (2008) Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Science 99: 1341–1347.
49. Koch A. Mancini A. El Bounkari O. Tamura T. (2005) The SH2-domain-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading. Oncogene 24: 3436–3447.
50. Krause D.S. Van Etten R.A. (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353: 172–187.
51. Kuniyasu H. Yasui W. Kitadai Y. Yokozaki H. Ito H. Tahara E. (1992) Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 189: 227–232.
52. Lai A.Z. Abella J.V. Park M. (2009) Crosstalk in Met receptor oncogenesis. Trends Cell Biol 19: 542–551.
53. Lengyel E. Prechtel D. Resau J.H. Gauger K. Welk A. Lindemann K. (2005) C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 113: 678–682.
54. Liang T.J. Reid A.E. Xavier R. Cardiff R.D. Wang T.C. (1996) Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J Clin Invest 97: 2872–2877.
55. Liu C. Park M. Tsao M.S. (1992) Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene 7: 181–185.
56. Liu X. Yao W. Newton R.C. Scherle P.A. (2008) Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 17: 997–1011.
57. Liu Y. Yang J. (2006) Hepatocyte growth factor: new arsenal in the fights against renal fibrosis?. Kidney Int 70: 238–240.
58. Lutterbach B. Zeng Q. Davis L.J. Hatch H. Hang G. Kohl N.E. (2007) Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 67: 2081–2088.
59. Machide M. Hashigasako A. Matsumoto K. Nakamura T. (2006) Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase. J Biol Chem 281: 8765–8772.
60. Maroun C.R. Naujokas M.A. Park M. (2003) Membrane targeting of Grb2-associated binder-1 (Gab1) scaffolding protein through Src myristoylation sequence substitutes for Gab1 pleckstrin homology domain and switches an epidermal growth factor response to an invasive morphogenic program. Mol Biol Cell 14: 1691–1708.
61. Matsumoto K. Nakamura T. (2006) Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer 119: 477–483.
62. Maulik G. Madhiwala P. Brooks S. Ma P.C. Kijima T. Tibaldi E.V. (2002a) Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med 6: 539–553.
63. Maulik G. Shrikhande A. Kijima T. Ma P.C. Morrison P.T. Salgia R. (2002b) Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 13: 41–59.
64. Miller C.T. Lin L. Casper A.M. Lim J. Thomas D.G. Orringer M.B. (2006) Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 25: 409–418.
65. Nakamura T. Nishizawa T. Hagiya M. Seki T. Shimonishi M. Sugimura A. (1989) Molecular cloning and expression of human hepatocyte growth factor. Nature 342: 440–443.
66. Nakamura Y. Matsubara D. Goto A. Ota S. Sachiko O. Ishikawa S. (2008) Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines. Cancer Sci 99: 14–22.
67. Navab R. Liu J. Seiden-Long I. Shih W. Li M. Bandarchi B. (2009) Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia 11: 1292–1300.
68. Okada H. Kalluri R. (2005) Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis. Curr Mol Med 5: 467–474.
69. Okamoto W. Okamoto I. Yoshida T. Okamoto K. Takezawa K. Hatashita E. (2010) Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition. Mol Cancer Ther 9: 1188–1197.
70. Olaku V. Matzke A. Mitchell C. Hasenauer S. Sakkaravarthi A. Pace G. (2011) c-Met recruits ICAM-1 as a co-receptor to compensate for the loss of CD44 in the Cd44 null mice. Mol Biol Cell 22: 2777–2786.
71. Olivero M. Valente G. Bardelli A. Longati P. Ferrero N. Cracco C. (1999) Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer 82: 640–643.
72. Organ S.L. Tong J. Taylor P. St-Germain J.R. Navab R. Moran M.F. (2011) Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer. J Proteome Res 10: 3200–3211.
73. Orian-Rousseau V. Morrison H. Matzke A. Kastilan T. Pace G. Herrlich P. (2007) Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell 18: 76–83.
74. Palka H.L. Park M. Tonks N.K. (2003) Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. J Biol Chem 278: 5728–5735.
75. Park M. Dean M. Cooper C.S. Schmidt M. O'Brien S.J. Blair D.G. (1986) Mechanism of met oncogene activation. Cell 45: 895–904.
76. Paumelle R. Tulasne D. Kherrouche Z. Plaza S. Leroy C. Reveneau S. (2002) Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene 21: 2309–2319.
77. Pelicci G. Giordano S. Zhen Z. Salcini A.E. Lanfrancone L. Bardelli A. (1995) The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene 10: 1631–1638.
78. Pennacchietti S. Michieli P. Galluzzo M. Mazzone M. Giordano S. Comoglio P.M. (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347–361.
79. Peruzzi B. Bottaro D.P. (2006) Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12: 3657–3660.
80. Peschard P. Fournier T.M. Lamorte L. Naujokas M.A. Band H. Langdon W.Y. (2001) Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 8: 995–1004.
81. Petrelli A. Gilestro G.F. Lanzardo S. Comoglio P.M. Migone N. Giordano S. (2002) The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature 416: 187–190.
82. Ponzetto C. Bardelli A. Zhen Z. Maina F. dalla Zonca P. Giordano S. (1994) A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77: 261–271.
83. Puri N. Salgia R. (2008) Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog 7: 9–9.
84. Rahimi N. Hung W. Tremblay E. Saulnier R. Elliott B. (1998) c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J Biol Chem 273: 33714–33721.
85. Rahimi N. Tremblay E. McAdam L. Park M. Schwall R. Elliott B. (1996) Identification of a hepatocyte growth factor autocrine loop in a murine mammary carcinoma. Cell Growth Differ 7: 263–270.
86. Rodrigues G.A. Park M. (1994) Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene 9: 2019–2027.
87. Rodrigues G.A. Park M. Schlessinger J. (1997) Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J 16: 2634–2645.
88. Rong S. Vande Woude G.F. (1994) Autocrine mechanism for met proto-oncogene tumorigenicity. Cold Spring Harbor Symp Quant Biol 59: 629–636.
89. Sakkab D. Lewitzky M. Posern G. Schaeper U. Sachs M. Birchmeier W. (2000) Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL. J Biol Chem 275: 10772–10778.
90. Sangwan V. Paliouras G.N. Abella J.V. Dube N. Monast A. Tremblay M.L. (2008) Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase. J Biol Chem 283: 34374–34383.
91. Schaeper U. Gehring N.H. Fuchs K.P. Sachs M. Kempkes B. Birchmeier W. (2000) Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J Cell Biol 149: 1419–1432.
92. Schmidt C. Bladt F. Goedecke S. Brinkmann V. Zschiesche W. Sharpe M. (1995) Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373: 699–702.
93. Schmidt L. Duh F.M. Chen F. Kishida T. Glenn G. Choyke P. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16: 68–73.
94. Schmidt L. Junker K. Nakaigawa N. Kinjerski T. Weirich G. Miller M. (1999) Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18: 2343–2350.
95. Sen B. Peng S. Saigal B. Williams M.D. Johnson F.M. (2011) Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin Cancer Res 17: 514–524.
96. Sharma S.V. Bell D.W. Settleman J. Haber D.A. (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169–181.
97. Sharma S.V. Settleman J. (2007) Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21: 3214–3231.
98. Sierra J.R. Corso S. Caione L. Cepero V. Conrotto P. Cignetti A. (2008) Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med 205: 1673–1685.
99. Smolen G.A. Sordella R. Muir B. Mohapatra G. Barmettler A. Archibald H. (2006) Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 103: 2316–2321.
100. Soman N.R. Correa P. Ruiz B.A. Wogan G.N. (1991) The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci USA 88: 4892–4896.
101. Stoker M. Gherardi E. Perryman M. Gray J. (1987) Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327: 239–242.
102. Syed Z.A. Yin W. Hughes K. Gill J.N. Shi R. Clifford J.L. (2011) HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer 11: 180–180.
103. Tong C.Y. Hui A.B. Yin X.L. Pang J.C. Zhu X.L. Poon W.S. (2004) Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J Neurosurg 100(2 Suppl Pediatrics): 187–193.
104. Trusolino L. Bertotti A. Comoglio P.M. (2001) A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 107: 643–654.
105. Trusolino L. Bertotti A. Comoglio P.M. (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11: 834–848.
106. Trusolino L. Comoglio P.M. (2002) Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2: 289–300.
107. Tsao M.S. Liu N. Chen J.R. Pappas J. Ho J. To C. (1998) Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 20: 1–16.
108. Tuck A.B. Park M. Sterns E.E. Boag A. Elliott B.E. (1996) Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 148: 225–232.
109. Uehara Y. Minowa O. Mori C. Shiota K. Kuno J. Noda T. (1995) Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373: 702–705.
110. Ueki T. Kaneda Y. Tsutsui H. Nakanishi K. Sawa Y. Morishita R. (1999) Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 5: 226–230.
111. Vadnais J. Nault G. Daher Z. Amraei M. Dodier Y. Nabi I.R. (2002) Autocrine activation of the hepatocyte growth factor receptor/met tyrosine kinase induces tumor cell motility by regulating pseudopodial protrusion. J Biol Chem 277: 48342–48350.
112. Watanabe M. Ebina M. Orson F.M. Nakamura A. Kubota K. Koinuma D. (2005) Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis. Mol Ther 12: 58–67.
113. Weidner K.M. Arakaki N. Hartmann G. Vandekerckhove J. Weingart S. Rieder H. (1991) Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA 88: 7001–7005.
114. Weidner K.M. Di Cesare S. Sachs M. Brinkmann V. Behrens J. Birchmeier W. (1996) Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384: 173–176.
115. Xiao G.H. Jeffers M. Bellacosa A. Mitsuuchi Y. Vande Woude G.F. Testa J.R. (2001) Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 98: 247–252.
116. Yeh C.Y. Shin S.M. Yeh H.H. Wu T.J. Shin J.W. Chang T.Y. (2011) Transcriptional activation of the Axl and PDGFR-alpha by c-Met through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer 11: 139–139.
117. Zhang Y.W. Wang L.M. Jove R. Vande Woude G.F. (2002) Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 21: 217–226.
118. Zhu H. Naujokas M.A. Park M. (1994) Receptor chimeras indicate that the met tyrosine kinase mediates the motility and morphogenic responses of hepatocyte growth/scatter factor. Cell Growth Differ 5: 359–366.